Geoff Meacham, senior pharma analyst, BofA Securities, on what Merck's new Covid treatment could mean for the company and the industry, as a whole. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Nadine Terman.
- Category
- Health
Be the first to comment